IntraOp announces the enrolment of first patients in Impulse Trial

U.S.-based medical equipment manufacturer, IntraOp Medical Corporation has reportedly announced that Lausanne University Hospital (CHUV, Switzerland) has enrolled first patients in the Impulse Trial, a phase I dose-aggravation assessment that studies high dose rate radiotherapy using electrons in patients who have developed skin metastases from cancer melanoma.

As per sources, the trial is a major milestone for the groundbreaking research collaboration agreement that was executed between the CHUV and IntraOp in 2020. The Impulse Trial is the first at the global level to assess the potential of leveraging the biological phenomenon called the “FLASH Effect” for the provision of radiotherapy with curative intent to cancers that are radio-resistant.

According to Professor Jean Bourhis, Principal Investigator and the Head of Radiation Oncology at CHUV, the Impulse Trial represents the first in a series of clinical trials that have been outlined for better understanding the potential of the FLASH effect. Bourhis also added that melanoma is one of the most radio-resistant cancers and it is rarely possible to conduct curative therapy with traditional radiotherapy.

For conducting the study, researchers will be deploying the IntraOp Mobetron platform that has been modified for delivering precision electron beam therapy at high dose rates for the production of the FLASH effect.

As per Kenneth Brooks, Ph.D., IntraOp’s Vice President of Sales and Corporate Strategy, by leveraging their extensive experience studying FLASH with an experimental LINAC, the researchers at CHUV have diligently worked over the past year for preparing the FLASH ability of the Mobetron for biological and now human clinical work.

Brooks further stated that via its capabilities of fine beam structure control that are now certified, the Mobetron is the obvious alternative for researchers who, similar to those at the CHUV, are looking for exploring the possible impacts of changing fine structure on the basic science behind this biologic effect.

Source credit: https://www.prnewswire.com/news-releases/intraop-announces-first-patients-enrolled-in-flash-clinical-trial-301327540.html